ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3039

Possible Contribution of HLA-A0207, B5201 and IL-23 Receptor Polymorphism in Ocular Behçet Disease

Toshikatsu Kaburaki1, Shinji Harihara2, Rie Tanaka3, Hiromasa Sawamura4, Ai Nishi4, Atsushi Hatamochi5, Jun Shimizu6, Masumi Takeuchi7, Shoji Kuwata8, Hidetoshi Kawashima9 and Fujio Takeuchi10, 1Ophthalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2Division of Anthropology, Department of Biological Science, The University of Tokyo Graduate School of Science, Tokyo, Japan, 3Department of Ophtalmology, The University of Tokyo Graduate School of Medicine,, Tokyo, Japan, 4Department of Ophtalmology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, 5Department of Dermatology, Dokkyo Medical University, Tochigi, Japan, 6Department of Neurology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, 7Teikyo University Support Center for Women Physicians and Researchers, Teikyo University School of Medicine, Tokyo, Japan, 8Third Department of Internal Medicine, Teikyo University Chiba Medical Center, Teikyo University School of Medicine, Chiba, Japan, 9Department of Ophthalmology, Jichi Medical University, Tochigi, Japan, 10Department of Allergy and Rheumatology, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Behcet's syndrome, human leukocyte antigens (HLA), interleukins (IL), polymorphism and uveitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Vasculitis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Behçet’s disease (BD) is known to be associated with
HLA-B*51:01 and HLA- A*26:01 in many different ethnic groups. Recently, HLA-A*02:07,
IL-10 and IL23R-IL12RB polymorphisms have been proposed as a candidate gene for
BD susceptibility.  In this study,
we examined the association of the HLA-A*02:07 and
single nucleotide polymorphism (SNP) of rs1495966
located in IL23R/IL12RB region using Japanese ocular BD patients.

Methods: One hundred and
thirty-six Japanese BD patients who suffered from uveitis and 213 healthy
controls were enrolled for analysis of polymorphisms of HLA class Iand the SNP of
rs1495966.  Statistical analysis was
performed mainly with odds ratio (OR) with 95% confidential interval
(95%CI).  Fisher’s exact test was
also carried out and the significance (p) was corrected by the numbers of
alleles compared (pc).

Results: Twenty three and 49 alleles were observed for HLA-A and
B, respectively. The phenotype frequencies (PF) of HLA-B*51:01 was significantly
higher in BD patients (44.1%) than in controls (15.5%) (OR=4.31 (95%CI=2.61-7.12),
pc=3.2x10E-7). The PF of HLA-A*26:01 was also significantly more frequent in BD
patients (35.3%) than in controls (15.5%) (OR=2.98 (1.78-4.96), pc=6.4x10E-4). The
PF of the BD patients carrying the A*26:01 or B*51:01 was extremely increased
comparing to the frequency in the control (71.3% Vs 28.2%, OR=6.34 (3.94-10.22),
pc=2.1x10E-12 (corrected by 23×49)).  The PF of B*5201 was significantly
decreased in BD (10.3% Vs 25.4%, OR=0.34 (0.18-0.63, pc=0.024).  The PF of the HLA-A*02:07 tended to be
increased in the BD-group without A*26:01 and B*51:01 (17.9% Vs 7.2%, OR=2.82
(1.02-7.85), pc= not significant (NS)). In addition, the PF of the HLA-B*39 was
increased in the BD-group without A*26:01 and B*51:01 (17.9% Vs 3.3%, OR=6.48
(1.93-21.70), pc= NS).  The allele
frequency (AF) of rs1495966*A allele in IL23R/IL12RB region was significantly
increased in BD patients (53.7%) than in controls (44.8%) (OR=1.43 (1.05-1.93),
pc=0.024).   In clinical
analysis, the PF of the B*51:01 was significantly associated with complete type
of BD (p=0.0416). The PF of the A*26:01 tended to be associated with
posterior/panuveitis (p=0.0979). The AF of GG in IL-23R SNP tended to be
associated with poor visual prognosis corresponding the best corrected-visual
acuity of 0.1 or less in the worse eyes (p=0.0643).

Conclusion: Our results indicated that, (1) HLA-A*02:07 is
another susceptibility gene for BD, associating independently from the B*51:01
and A*26:01, (2) HLA-B*39 is possibly associated with BD, (3) B*52:01 is a
protective allele for ocular BD in Japan, (4) rs1495966*A is associated with BD
and might be a disease marker for the severity of ocular disease.


Disclosure: T. Kaburaki, None; S. Harihara, None; R. Tanaka, None; H. Sawamura, None; A. Nishi, None; A. Hatamochi, None; J. Shimizu, None; M. Takeuchi, None; S. Kuwata, None; H. Kawashima, None; F. Takeuchi, None.

To cite this abstract in AMA style:

Kaburaki T, Harihara S, Tanaka R, Sawamura H, Nishi A, Hatamochi A, Shimizu J, Takeuchi M, Kuwata S, Kawashima H, Takeuchi F. Possible Contribution of HLA-A0207, B5201 and IL-23 Receptor Polymorphism in Ocular Behçet Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/possible-contribution-of-hla-a0207-b5201-and-il-23-receptor-polymorphism-in-ocular-behcet-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/possible-contribution-of-hla-a0207-b5201-and-il-23-receptor-polymorphism-in-ocular-behcet-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology